We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+12.53%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.25B
AUM Growth
+$307M
(+10%)
Cap. Flow
+$95.8M
Cap. Flow
% of AUM
2.95%
Top 10 Holdings %
Top 10 Hldgs %
41.75%
Holding
101
New
19
Increased
28
Reduced
23
Closed
18
Avg Time Held
1
year
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$68.6M |
| 2 |
Allakos
ALLK
|
+$59.9M |
| 3 |
WMGI
Wright Medical Group Inc
WMGI
|
+$58.6M |
| 4 |
Fate Therapeutics
FATE
|
+$43.8M |
| 5 |
Replimune Group
REPL
|
+$38.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$60.7M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$56.5M |
| 3 |
Labcorp
LH
|
+$51.8M |
| 4 |
Insmed
INSM
|
+$48.1M |
| 5 |
Centene
CNC
|
+$39.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.24% |
| 2 | Miscellaneous | 1.57% |
| 3 | Financials | 1.28% |
| 4 | Energy | 0.69% |
| 5 | Technology | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Jazz Pharmaceuticals
JAZZ
$13.6B
| $267K | 0.01% |
1,590
| – | – |
2018 Q2
1 quarter
|
|
77
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $248K | 0.01% |
13,260
| – | – |
2018 Q1
2 quarters
|
|
78
Senseonics Holdings Inc
SENS
$428M
| $214K | 0.01% |
2,245
-63,651
| -97% | -$5.21M |
2018 Q2
1 quarter
|
|
79
Aclaris Therapeutics
ACRS
$498M
| $164K | 0.01% |
11,320
-95,500
| -89% | -$1.64M |
2016 Q4
7 quarters
|
|
80
DELISTED
Adverum Biotechnologies
ADVM
| $135K | ﹤0.01% |
2,224
| – | – |
2016 Q2
9 quarters
|
|
|
CSLT
81
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $28K | ﹤0.01% |
10,229
| – | – |
2018 Q2
1 quarter
|
|
82
Abbott
ABT
$178B
| – | – |
-449,300
| Closed | -$27.4M | – |
|
83
Accuray
ARAY
$20.9M
| – | – |
-29,000
| Closed | -$119K | – |
|
84
Bausch Health
BHC
$2.2B
| – | – |
-8,930
| Closed | -$208K | – |
|
85
CytomX Therapeutics
CTMX
$486M
| – | – |
-262,400
| Closed | -$6M | – |
|
86
Immunic
IMUX
$90.9M
| – | – |
-2,738
| Closed | -$7.5M | – |
|
|
87
Insmed
INSM
$21.4B
| – | – |
-2,033,492
| Closed | -$48.1M | – |
|
88
Inspire Medical Systems
INSP
$1.97B
| – | – |
-200,000
| Closed | -$7.13M | – |
|
89
iRhythm Holdings
IRTC
$3.5B
| – | – |
-401,303
| Closed | -$32.6M | – |
|
|
90
Labcorp
LH
$25.7B
| – | – |
-335,698
| Closed | -$51.8M | – |
|
91
Sarepta Therapeutics
SRPT
$1.78B
| – | – |
-31,100
| Closed | -$4.11M | – |
|
92
Teleflex
TFX
$5.22B
| – | – |
-79,886
| Closed | -$21.4M | – |
|
93
DELISTED
Unity Biotechnology
UBX
| – | – |
-25,040
| Closed | -$3.77M | – |
|
94
aTyr Pharma
ATYR
$18M
| – | – |
-134,642
| Closed | -$1.72M | – |
|
95
DELISTED
NEVRO CORP.
NVRO
| – | – |
-3,400
| Closed | -$271K | – |
|
96
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| – | – |
-179,083
| Closed | -$7.67M | – |
|
|
VRAY
97
DELISTED
ViewRay, Inc.
VRAY
| – | – |
-24,330
| Closed | -$168K | – |
|
|
ALXN
98
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-489,300
| Closed | -$60.7M | – |
|
|
HZNP
99
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-25,800
| Closed | -$427K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q3 2018 Portfolio in Review
As of Q3 2018, Redmile Group held 101 positions worth $3.25B, up 10% from $2.94B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Redmile Group's Q3 2018 filing shows 19 new, 28 increased, 23 reduced and 18 closed positions. Its largest new stake was Cigna: 370,200 shares worth $77.1M. The largest sale was Alexion Pharmaceuticals, an estimated $60.7M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Miscellaneous and Financials.
- Redmile Group's largest Q3 2018 buy was Cigna: 370,200 shares worth $77.1M.
- Redmile Group added most to Fate Therapeutics in Q3 2018, an estimated $43.8M increase.
- Redmile Group's biggest Q3 2018 reduction was Wellcare Health Plans, Inc., cutting an estimated $56.5M.
- Redmile Group fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $60.7M.
- Redmile Group's ten largest holdings make up 42% of its $3.25B portfolio in Q3 2018.
- Redmile Group opened 19 new positions and closed 18 in Q3 2018.
- Redmile Group's portfolio value rose 10% quarter-over-quarter to $3.25B.
Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.